BACKGROUND: Opioids and nitric oxide (NO) are functionally linked in the regulation of intestinal motility. OBJECTIVES: To investigate the role of NO in the opium induced bowel dysfunction in mice. METHODS: Sixty-six male mice received incrementally doses of the following treatments in six groups for 5 consecutive days: 1) Opium (0.2, 0.3, 0.4, 0.5 and 0.6mg/30g/day), 2) N-nitro-L-arginine methyl ester (L-NAME, 5,7.5,10,15 and 20mg/kg/day), 3) L-arginine (5-20mg/kg/day), 4) Opium+L-NAME, 5) Opium+L-arginine and 6) distilled water. At the end of the treatment, the abdomen was opened; some pieces of duodenal and proximal colon were taken to determine NO synthase (NOS) expression and nitrite levels, and some isolated rings from those parts of small and large intestine were prepared and transferred to the organ bath system to study intestinal motility. RT-PCR was used to determine the NOS gene expression. To determine the small intestinal transit, 30 mice in six groups, were used for oral administration of charcoal+gum in vivo. RESULTS: Opium decreased amplitude of the duodenum and ileum contractions, but increased frequency of duodenal and mid colon contractions (P<0.05). While the gene expression of inducible, neuronal and endothelial NOS was increased in colon (P<0.05), a reduced neuronal and endothelial NOS gene expression was shown in duodenum. The charcoal+gum transit was decreased in opium-treated animals compared to the control group (19.9%). However, L-arginine increased this transit while L-NAME decreased it. CONCLUSIONS: Opium induced intestinal smooth muscle spasms, which result in the decreased intestinal movements. The alterations in NOS gene expression may be a compensation mechanism against opium-induced intestinal dysfunction.

BACKGROUND: Doxorubicin is one of the most widely used anticancer chemotherapeutic agents in small animal practice. The use of doxorubicin can cause cardiotoxicity, hepatotoxicity, neurotoxicity, and nephrotoxicity. OBJECTIVES: This study was carried out to evaluate the effects of ascorbic acid on doxorubicin hepatotoxicity in mice. METHODS: Twenty-four Balb/c mice were randomly divided into four groups. Group one received normal saline, group two received 100 mg/kg ascorbic acid, group three received 8 mg/kg doxorubicin and group four received ascorbic acid and doxorubicin intraperitoneally, with the same doses of groups 2 and 3. Twenty-one days after injection, the mice were euthanized. The activities of ALP, ALT, AST enzymes and total bilirubin levels in the serum samples were measured. Liver samples were evaluated histopathologically. RESULTS: The activities of ALP, ALT, AST, and total bilirubin levels and histopathologic scores of hepatotoxicity were significantly lower in the group that received ascorbic acid + doxorubicin in comparison to those of the doxorubicin group. CONCLUSIONS: Ascorbic acid may be useful in the prevention of doxorubicin hepatotoxicity in mice. Further studies are recommended for evaluation of the use of ascorbic acid in small animals.